Indirect Comparison Between Eltrombopag & Romiplostim

Meta-analysis - Eltrombopag

NCT01235988 ·Status: COMPLETED

Efficacy and Safety Study of Eltrombopag in Pediatric Patients With Thrombocytopenia From Chronic Idiopathic Thrombocytopenic Purpura (ITP)

NCT00908037 ·Status: COMPLETED ·Phase: PHASE2

Thrombopoietin Agonists in Patients With Idiopathic Thrombocytopenic Purpura

NCT06137105 ·Status: NOT_YET_RECRUITING

Safety and Efficacy Study of Romiplostim (AMG 531) to Treat ITP in Pediatric Subjects

NCT00515203 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients

NCT01444417 ·Status: COMPLETED ·Phase: PHASE3

Romiplostim (AMG 531) Versus Medical Standard of Care for Immune (Idiopathic) Thrombocytopenic Purpura

NCT00415532 ·Status: COMPLETED ·Phase: PHASE3

A Study to Assess the Ability of Eltrombopag to Induce Sustained Response Off Treatment in Subjects With ITP

NCT03524612 ·Status: COMPLETED ·Phase: PHASE2

Safety and Efficacy of Romiplostim in Immune Thrombocytopenia (ITP) in the " Real-life " : Result of the French Experience in 72 Adults

NCT01013181 ·Status: COMPLETED

Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body.

NCT01520909 ·Status: COMPLETED ·Phase: PHASE3

TPO-mimetics Before Splenectomy in Adult Primary Immune Thrombocytopenia Patients.

NCT02063763 ·Status: COMPLETED

Efficacy and Safety of Romiplostim Versus Eltrombopag in the Treatment of Thrombocytopenia in Patients With Wiskott-Aldrich Syndrome

NCT04371939 ·Status: UNKNOWN ·Phase: PHASE2

Safety and Treatment Satisfaction in Adults With Chronic ITP After Switching to Avatrombopag From Eltrombopag or Romiplostim

NCT04638829 ·Status: COMPLETED ·Phase: PHASE4

A Study Evaluating the Safety and Efficacy of Long-term Dosing of Romiplostim in Thrombocytopenic Pediatric Patients With Immune (Idiopathic) Thrombocytopenia Purpura

NCT01071954 ·Status: COMPLETED ·Phase: PHASE3

Response Rate and Duration After Discontinuation Thrombopoietin Receptor Agonists Primary Immune Thrombocytopenia

NCT02298075 ·Status: COMPLETED

Association of FcγRIIIA Polymorphism and THPO Expression With Response to Eltrombopag in Refractory ITP Patients

NCT02877212 ·Status: UNKNOWN ·Phase: PHASE3

An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With ITP

NCT00508820 ·Status: COMPLETED ·Phase: PHASE3

Amgen Megakaryopoiesis Protein 2 (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)

NCT00117143 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Efficacy and Safety of Romiplostim N01 Combined With Rituximab in Patients With Oral TPO-RA-Refractory Primary Immune Thrombocytopenia

NCT07206823 ·Status: RECRUITING ·Phase: NA

Study of Romiplostim for Chemotherapy Induced Thrombocytopenia

NCT02052882 ·Status: COMPLETED ·Phase: PHASE2

Romiplostim Treatment for Thrombocytopenia in Patients With Wiskott-Aldrich Syndrome.

NCT04350164 ·Status: COMPLETED

Role of Eltrombopag as First Line Therapy in Primary Immune Thrombocytopenia.

NCT06531018 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Long-term Study of Romiplostim in Thrombocytopenic Pediatric Patients With Immune Thrombocytopenia (ITP)

NCT02279173 ·Status: COMPLETED ·Phase: PHASE3

Open Label Extension Study of Romiplostim (AMG 531) in Thrombocytopenic Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

NCT00116688 ·Status: COMPLETED ·Phase: PHASE3

Eltrombopag for Thrombocytopenia in Patients With Relapsed Multiple Myeloma

NCT01484314 ·Status: TERMINATED ·Phase: PHASE2

An Observational Study to Evaluate the Efficacy of Biweekly Romiplostim in Adult Patients With ITP

NCT02338414 ·Status: UNKNOWN ·Phase: PHASE2